Stability of biopharmaceuticals is a complex matrix of parameters that plays a crucial role through the entire product life-cycle. Through case studies, we discuss how Prometheus provides clarity by delivering precise and reliable stability measurements, outperforming existing tools, to inform critical decisions throughout the product life-cycle.
Most recent content
Regardless of fluorescence technology (i.e Spectral Shift, TRIC, or FRET), optimizing your labeling strategy is essential to minimize impact on the functionality and ensure accurate Kd measurements
Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
Many methods used in fragment-based drug discovery pose real challenges — SPR often struggles to detect true hits due to fragments’ small mass, DSF can have high rates of false positives, and NMR equi
Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.
Learn how to identify optimal buffer conditions during pre-formulation, with multi-parameter stability characterization from Prometheus Panta, a tool to collect thermal and colloidal data while saving
Characterize the developability of antibody-drug conjugates: Multi-parameter stability assessment with Prometheus Panta makes it possible to examine multiple aspects of ADC stability in parallel.
For antibody-drug conjugate (ADC) development, scientists rely on stability experiments using fluorescence and light scattering techniques to predict the conjugated molecule's behavior.
To understand signaling pathways, Spectral Shift technology allows for accurate bindings affinity measurements of membrane proteins like GPCRs in close to native conditions.
Transcription factors have traditionally been considered challenging therapeutic targets. Their intrinsic disorder and lack of small molecule binding pockets make them intractable to small molecule ap
MYC is an important therapeutic target that associates with MAX to regulate gene transcription. Its lack of binding pockets and the presence of disordered regions make it a difficult protein to study
Join this conversation to gain insight into how the Analytical and Formulation Sciences team at Thermo Fisher Scientific approaches stability assessment of biologic, and how the Prometheus Panta helps
To assess the developability properties of antibody-drug conjugates (ADCs) learn about multi-parameter characterization of thermal and colloidal stability with Prometheus Panta using nanoDSF and DLS
Thermal stability screening is a common approach used to study the developability of a wide range of protein-based therapeutics. Among the different technologies available to perform thermal stability
Learn about four methods for thermal stability measurements: DSC, CD, DSF and nanoDSF. You'll review their pros and cons, what they data tell you and why it's important for biologics developability.
Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the cl
In this video, Nathan Wallace, Application Specialist at NanoTemper, addresses common questions about experimental design for developability profiling and the operation of Prometheus Panta.
Developability assessment is a critical part of the evaluation and selection of candidates for further optimization and development for biologics researchers. This work entails collecting, ranking, an
The development of your protein degrader is a multi-step and complex process usually packed with challenges that if left unsolved will delay the progress of your project. What if you could overcome co
Full developability profiles de-risk the selection process for biologics candidates during early development workflows. There are many critical quality attributes to evaluate when it comes to developa
Developability work requires the assessment of multiple critical quality attributes (CQAs) of your biologics. Many of these CQAs are measured or monitored using low-volume, low-concentration samples.